Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2008
10/07/2008US7431925 Internal image antibodies for optical imaging and therapy
10/07/2008US7431924 Antigen binding fragment binds to denatured polypeptide which chemoattracts peripheral blood monocytes or T-cells; immunizing animal
10/07/2008CA2444071C Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
10/07/2008CA2435946C Piperidine derivatives as neurokinin 1 antagonists
10/07/2008CA2433772C Pyrimidine matrix metalloproteinase inhibitors
10/07/2008CA2427573C Indole derivatives as pde5-inhibitors
10/07/2008CA2411544C N-alkyl-adamantyl triazinyl benzamide derivatives
10/07/2008CA2392971C 2,4-diaminopyrimidine compounds useful as immunosuppressants
10/07/2008CA2362831C Thioamide derivatives
10/07/2008CA2362582C Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
10/07/2008CA2331461C Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
10/07/2008CA2296067C Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
10/07/2008CA2181909C Aromatic 2-amino-imidazole derivatives as alpha-2a adrenoceptor agonists
10/07/2008CA2179955C Kappa-opiate agonists for inflammatory bowel disorders
10/07/2008CA2106061C Human follicle stimulating hormone receptor
10/02/2008WO2008118552A1 Use of ranolazine for the treatment of cardiovascular diseases
10/02/2008WO2008117862A1 Novel (2-aminophenyl)pyridinecarboxamide derivative having urea structure
10/02/2008WO2008117815A1 Inhibitor for cell death caused by endoplasmic reticulum stress or oxidation stress
10/02/2008WO2008117814A1 Oral pharmaceutical preparation for colon-specific delivery
10/02/2008WO2008117707A1 Ground crystal of olmesartan medoxomil
10/02/2008WO2008117523A1 Antiviral agent
10/02/2008WO2008116816A1 Combination of cb2 ligand and paracetamol
10/02/2008WO2008116809A1 Pharmaceutical compositions comprising a bisphosphonate and vitamin d
10/02/2008WO2008116347A1 Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
10/02/2008WO2008097897A3 Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1(pai-1)
10/02/2008WO2008079363A3 Substituted tetracycline compounds for treatment of inflammatory skin disorders
10/02/2008WO2008051505A8 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
10/02/2008WO2008015429A3 Pharmaceutical compounds
10/02/2008WO2008001101A3 Pharmaceutical combinations
10/02/2008WO2007059209A3 Extract of dioscorea sp. and the medical uses thereof
10/02/2008US20080242855 Process for Producing Flavone C Glycoside Derivatives
10/02/2008US20080242840 Saposin B specific monoclonal antibody for use in treatment and prevention of cell proliferative disorders
10/02/2008US20080242738 for cells, proteins, DNA or other molecules encapsulation; carragenan, chitosan, hyaluronic acid, cellulose or alginate; with thiophene, aniline or pyrrole polymerizable moiety grafted on
10/02/2008US20080242726 may contain both cis-clomiphene and trans-clomiphene, and the ratio of trans-clomiphene and cis-clomiphene may be greater than 71/29; extended release
10/02/2008US20080242719 Reduce tumor necrosis factor; phosphodiesterase inhibitor; antiinflammatory agents; anticancer agents; antidepressants; skin diosrders
10/02/2008US20080242679 Using 1-(2-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)2,3-dihydro-1H-benzimidazol-2-one
10/02/2008US20080242666 e.g. (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(1-ethylpropyl)-1-[2(hydroxymethyl)benzyl]-piperazine-2,5-dione; preparation by cyclization
10/02/2008US20080242662 substituted 3,4- or higher substituted piperazine compounds; renin inhibitor; antidiabetic, analgesic,hypotensive agent; neurodegenerative diseases; preparation by reacting a carbonic acid with amino compound
10/02/2008US20080242660 1,4-diazepin-1-sulfonyl-isoquinoline derivatives; Rho kinase, myosin light chain kinase or protein kinase C inhibitor; relaxing effect on vascular smooth muscles; hypotensive and vasodilating agent; occlusion or stenosis of an artery
10/02/2008US20080242637 Binding efficiency;cyxicity; therapy for lung, colon, ovariers tumor
10/02/2008US20080242628 In vivo
10/02/2008US20080242626 End-Modified Poly(beta-amino esters) and Uses Thereof
10/02/2008US20080242624 Cyclin D Polynucleotides, Polypeptides and Uses Thereof
10/02/2008US20080242619 Peptidomimetics ; determine ability to bind to growth hormone secretagogue; ghrelin antagonist; appetite stimulation; dietetics ; weight maintenance; eating disorders
10/02/2008US20080242605 Prevent binding of formyl methionine-leucine-phenylalanine and, or protein to granulocytes; antiinflammatory agents; viricides; HIV infections
10/02/2008US20080242591 Treating vascular malformation with nicotinic acetylcholine receptor (nAChR) antagonist; arthritis, cancer
10/02/2008US20080241923 Using cc-chemokine receptor 2 (CCR2) specific immunoglobulin for treatment and prevention of viral infection, inflammatory, autoimmune, graft rejection and cardivascular disorders
10/02/2008US20080241835 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
10/02/2008US20080241243 Biodegradable fibrillar collagen matrix; sustained release; postsurgery pain control
10/02/2008US20080241242 Porous Polyelectrolyte Materials
10/02/2008US20080241207 Culture medium; antibodies; bioassays; drug screening; administering with an agonist or antagonist; stromal cells; implants
10/02/2008US20080241194 Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage
10/02/2008US20080241188 Namely the hemagglutinin gene under control of the cytomegalovirus immediate early promoter; inoculating chickens; serological responses are easily detected by hemagglutination inhibition assay but not by diagnostic ELISA kits, enabling differentiation between vaccination and field infection
10/02/2008US20080241173 Using FLT3 kinase as tool in identifying modulators for treatment and prevention of hematopoietic stem cell disease
10/02/2008US20080241172 Mutated Cholinesterase Sequences, Corresponding Nucleic Acids And Their Uses
10/02/2008US20080241162 Hepatitis c viral E2 glycoprotein specific immunoglobulin for use in prevention and treatment of hepatitis infection
10/02/2008US20080241161 Liposome encapsulated antitumor immunoglobulin fusion for use in treatment of breast cell proliferative disorders
10/02/2008US20080241160 Interleukin-4 specific immunoglobulin for use in treatment and prevention of atopic, respiratory and allergic disorders
10/02/2008US20080241157 Nerve cell growth modulators (amphibodies)
10/02/2008US20080241153 Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof
10/02/2008US20080241152 Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof
10/02/2008US20080241147 Using pleckstrin homology (PH) domain-interacting protein as tool in detection and identification of modulators for prevention and treatment of cell proliferative disorders
10/02/2008US20080241146 Apo-2 ligand-anti-Her-2 antibody synergism
10/02/2008US20080241143 Using selectin therapeutic in treatment of inflammatory bowel and joint disorders
10/02/2008US20080241140 Gene amplification of coactivator coaa and uses thereof
10/02/2008US20080241137 Cancerous disease modifying antibodies
10/02/2008US20080241136 Using cc-chemokine receptor 2 (CCR2) specific immunoglobulins for use in treatment and prevention of skin disorders
10/02/2008US20080241135 Using humanized monoclonal antibody (POR140) as therapeutic to decrease viral particles in human immunodeficiency virus infected individuals; viricides; enzyme inhibitors
10/02/2008US20080241134 Uses of human monoclonal antibodies against oxidized ldl receptor
10/02/2008US20080241133 Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
10/02/2008US20080241131 Using sphingosine kinase-2 as tool in identifying modulators for use in treatment of cell proliferative disorders
10/02/2008US20080241120 Therapeutic mixturecomprising pilocarpine combined with bioadhesive polymer for use in treatment of reduced salivation
10/02/2008US20080241116 Using vector comprising nucleotide sequences coding serine phage intergrase to transfer heterologous nucleotide sequences into cells; inproving exogenous gene expression; gene therapy
10/02/2008US20080241115 Use Of Mesenchymal Stem Cells Genetically Modified To Express A Suicide Gene For Treating A Cancer
10/02/2008US20080241114 Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
10/02/2008US20080241111 Pluripotent Stem Cell Derived from Cardiac Tissue
10/02/2008US20080241103 Recombinant Virus Comprising an Intact Tumor-Therapeutic Antibody With Human Constant Regions and the Use Thereof
10/02/2008US20080241101 Nutrient broth comprising serine protease inhibitors and cytokine for use propgation of skin basement membrane tissues; regenerative medicine; tissue repair
10/02/2008US20080241099 Inhibitors of MBP 85-99 or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones; multiple sclerosis; rheumatoid arthritis; solid phase synthesis; kits
10/02/2008US20080241078 Compositions and methods for treating hair loss using c16-c20 aromatic tetrahydro prostaglandins
10/02/2008US20080241077 Benzoylguanidine salt and hydrates thereof
10/02/2008US20080241067 co-culturing cancer cells and host cells for a time sufficient to detect evidence of gene expression in co-culture for simulating the progression from a primary tumor to a metastasis in an in vitro model; anti-EphA2 ( epithelial cell kinase) antibody
10/02/2008CA2684655A1 Oral pharmaceutical preparation for colon-specific delivery
10/02/2008CA2681591A1 Pulverized crystals of olmesartan medoxomil
10/02/2008CA2680517A1 Novel pyridinecarboxylic acid (2-aminophenyl)amide derivative having urea structure
10/02/2008CA2678272A1 Use of ranolazine for the treatment of cardiovascular diseases
10/01/2008EP1975234A2 Therapeutic and diagnotics agents capable of modulating cellular responsiveness to cytokines
10/01/2008EP1975172A2 High affinity TGFß nucleic acid ligands and inhibitors
10/01/2008EP1975162A1 Oxazolone derivative
10/01/2008EP1974748A2 Antibodies for the diagnosis of diseases associated with fibrosis
10/01/2008EP1973543A2 Modulators of muscarinic receptors
10/01/2008EP1496877B1 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
10/01/2008EP1383496B1 Treatment of fibromyalgia using pindolol
10/01/2008EP1372655B1 Cathepsin cysteine protease inhibitors
10/01/2008EP1317274B1 Peptide composition for treatment of periodontal diseases and prevention of skin aging
10/01/2008EP1212295B1 Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
10/01/2008EP1091745B1 Treatment of hyperproliferative disorders
10/01/2008CN101277719A Medical agent containing insulin resistance improving agent
10/01/2008CN101277713A Composition for acceleration of type I collagen production
10/01/2008CN101277712A The composition comprising extract of cinnamomum cassia bark for improving normal flora and enhancing immune response
1 ... 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 ... 1564